CINCINNATI, Ohio – December 15, 2025 – LIB Therapeutics Inc. (LIB), a privately held biopharmaceutical company with a singular focus on helping high-risk patients achieve their cholesterol goals, today announced the U.S. Food and Drug Administration (FDA) has approved LEROCHOL™ (lerodalcibep-liga) injection for subcutaneous use as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).

THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha^® (evolucumab).

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S.

The National Lipid Association (NLA) today announced the release of a major new clinical guidance document titled “LDL Cholesterol Management Simplified in Adults – Lower for Longer is Better: Guidance from the National Lipid Association,” now available open access in the Journal of Clinical Lipidology. This expert consensus underscores a vital message for clinicians and patients alike: lowering LDL-C early, intensively, and sustainably is critical to reducing the risk of cardiovascular events.

Watch PLA leadership discuss the importance of lipid management and the NLA’s role in advancing cardiometabolic care.

The National Lipid Association (NLA) has released a comprehensive clinical review titled “Familial Chylomicronemia Syndrome: An Expert Clinical Review from the National Lipid Association.” This new guidance provides an in-depth examination of the diagnosis, management, and treatment landscape for familial chylomicronemia syndrome (FCS) — a rare and severe genetic disorder characterized by extremely high triglyceride levels (≥ 1,000 mg/dL) and an elevated risk of life-threatening recurrent acute pancreatitis.